111 results on '"Espirito, Janet L."'
Search Results
2. Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
3. Real-world study of patients with HR+/ HER2- metastatic breast cancer treated with palbociclib and fulvestrant.
4. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network
5. Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists
6. Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
7. Treatment Patterns and Clinical Outcomes Among Metastatic Non–Small-Cell Lung Cancer Patients Treated in the Community Practice Setting
8. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors
9. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer
10. Feasibility of Using Oncology-Specific Electronic Health Record (EHR) Data to Emulate Clinical Trial Eligibility Criteria
11. Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
12. Treatment patterns and outcomes in metastatic synovial sarcoma: a real-world study in the US oncology network
13. Predictors of biomarker testing among patients (pts) with metastatic non–small cell lung cancer (mNSCLC).
14. Real-world outcomes of systemic therapy in locally advanced, recurrent or metastatic cutaneous squamous cell carcinoma
15. The Friends of Cancer Research Real‐World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies
16. Real‐world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research Pilot
17. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting
18. Evaluating real-world overall survival (rwOS) across oncology data sources: Friends of Cancer Research non-small cell lung cancer pilot study.
19. Real-world disease burden and outcomes of brain metastases in EGFR mutation-positive non-small-cell lung cancer
20. Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy
21. Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration.
22. Chapter 6 Progestins and androgens
23. Paclitaxel-induced sickle cell crisis
24. Real‐world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research Pilot.
25. The Friends of Cancer Research Real‐World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies.
26. Treatment patterns and outcomes among patients with advanced cutaneous squamous cell carcinoma (CSCC) in a US community oncology setting.
27. Real-world disease burden and outcomes of brain metastases in mutation-positive non-small-cell lung cancer.
28. Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting
29. Adjuvant therapy utilization among stage III melanoma patients.
30. Understanding treatment patterns and outcomes in patients with metastatic NSCLC treated in a US community oncology network.
31. Treatment outcomes with first-line (1L) nab-Paclitaxel + gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma (mPAC).
32. Sustained impact of primary platinum-free interval and BRCA1/2 mutation status on survival in patients with ovarian cancer after multiple lines of therapy.
33. Early treatment utilization of palbociclib for metastatic breast cancer (MBC) in a U.S. community oncology network.
34. Outcomes by schedule and line of therapy in patients (pts) with metastatic breast cancer (MBC) treated with nab-paclitaxel (nab-P): A U.S. retrospective, community-based, real-world cohort analysis.
35. Treatment patterns and outcomes in metastatic colorectal cancer (mCRC).
36. Treatment Patterns and Economic Assessment of Systemic Therapy for Metastatic Colorectal Cancer
37. Impact of social determinants of health (SDOH) measures on prescribing advanced androgen blockade (AAB) in patients with metastatic hormone sensitive prostate cancer (mHSPC).
38. Assessment of genomic profiling in patients with colorectal cancer treated in community oncology practices.
39. Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.
40. Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets.
41. Social determinants of health and utilization of neoadjuvant chemotherapy in patients with triple negative breast cancer (TNBC) in the community oncology setting.
42. The impact of social determinants of health (SDOH) on use of germline genetic testing for triple-negative breast cancer (TNBC) in the community oncology setting.
43. Vitamin D levels, triple-negative histology, and geography in breast cancer: A retrospective analysis of a large database of oncology practices in the United States.
44. Secondary nonbreast malignancies (SNBM) after primary breast cancer (BC).
45. Bridging to survivorship in breast cancer: Learning how treatment impacts mental health among early-stage breast cancer survivors.
46. Bridging to survivorship in breast cancer: How BMI weighs in.
47. Patient-reported symptoms obtained through telephonic nursing services in an oncology disease management program.
48. Pathways, Outcomes, and Costs in Colon Cancer: Retrospective Evaluations in Two Distinct Databases
49. Clinical outcomes of a pharmacist-managed anticoagulation service for breast cancer patients
50. Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.